score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	AURKB	Amplification				0.0	0.0		Putatively Actionable	Barasertib	Aurora-B kinase inhibition	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298													0				AURKB Amplification		KIRP-B1-A657	TCGA-B1-A657-01	
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.Q110fs	0.3089	123.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	PTEN p.Q110fs (Frameshift)	1.0	KIRP-B1-A657	KIRP-B1-A657-TP	KIRP-B1-A657-NB
Biologically Relevant				Somatic Variant	TPX2	Missense	p.C747F	0.3333	60.0	0.0	0.0																					0	0.0	0.0	0.0	TPX2 p.C747F (Missense)		KIRP-B1-A657	KIRP-B1-A657-TP	KIRP-B1-A657-NB
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		KIRP-B1-A657		
Biologically Relevant				Mutational Signature	COSMIC Signature 20	version 2	0.212																									0				COSMIC Signature (version 2) 20 (21%)		KIRP-B1-A657		
